glp·helper
glphelper.com/ozempic/illinois/arlington-heights
GLP-1 receptor agonistFDA-approved December 2017Rx · Subcutaneous injection · Once weekly

Ozempic® providers &
prescriptions in Arlington Heights, IL

Verified Ozempic providers in Arlington Heights, IL. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Ozempic weight loss →trial-anchored estimate
city providers
33
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Illinois
33 of 33 shown

Find an Ozempic provider in Illinois.

Every entry is checked against the NPI registry and the Illinois medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Illinois city · /ozempic/illinois/{city}
§ 03Getting Ozempic in Arlington Heights
33 providers · Arlington Heights, IL

How to get Ozempic in Arlington Heights.

33 GLP-1 prescribers and 7 local resource types are on record for Arlington Heights, plus 3 nearby towns in the directory.

Prescribers in Arlington Heights
33 prescribers
33 GLP-1 prescribers in Arlington Heights, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (11), Family Medicine (11) and Internal Medicine (9). Any Illinois-licensed physician, nurse practitioner, or PA can prescribe Ozempic, over video or in person. The nearest towns on record are Schaumburg (24 providers), Oak Park (30 providers) and Elgin (21 providers).
Around the prescription in Arlington Heights
7 listed nearby
24 dietitians, 3 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Arlington Heights.
Medicaid (weight loss)
Diabetes only
As of April 2026, Illinois Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Illinois’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes, and, by indirect effect, for body weight.

Ozempic is the brand name for semaglutide, a once-weekly subcutaneous injection in the GLP-1 receptor agonist class. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. In randomized trials it lowered HbA1c by 1.4 to 1.8 percentage points and produced a mean weight loss of 4.5 to 6.4 kg at the 1 mg dose.[2][3]

It is FDA-approved for glycemic control in adults with type 2 diabetes mellitus and for reducing the risk of major cardiovascular events in adults with T2D and established cardiovascular disease. The same molecule, marketed by the same manufacturer as Wegovy, is the FDA-approved formulation for chronic weight management.[1]

For the receptor story in plain English, read how does ozempic work.

Rapid weight loss can change the midface. The mechanism people call ozempic face is in the research notes.

At a glanceNDC 0169-4132
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Wegovy is the FDA-approved formulation for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 2 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Arlington Heights

Arlington Heights, Illinois has a population of 77,676 people. The adult obesity rate in Arlington Heights is an age-adjusted estimate of 24.9%, 9.3 percentage points below the Illinois state rate of 34.2%. Diagnosed diabetes reaches 7.2% of adults in Arlington Heights. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 15.7% of adults in Arlington Heights.

of Arlington Heights adults have obesity
24.9%
diagnosed diabetes
7.2%
no regular physical activity
15.7%

Age-adjusted estimates for Arlington Heights, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossmale-specific GLP-1 side effects
§ 05Support around Ozempic in Arlington Heights
6 fitness clubs

The prescription is one part. Here is the rest, in Arlington Heights.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Arlington Heights, IL, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Arlington Ridge Center
FITNESS
4.4 on Google · 397 reviews
660 N Ridge Ave
Website
Inspyr Studios
FITNESS
5.0 on Google · 388 reviews
2924 W Euclid Ave
Website
Endeavor Health Fitness & Wellness Center - NCH
FITNESS
4.5 on Google · 289 reviews
900 Central Rd
Website
Commuter Fitness
FITNESS
4.8 on Google · 35 reviews
506 W Northwest Hwy
Website
Empowered Fitness & Recovery
FITNESS
5.0 on Google · 27 reviews
3350 Salt Creek Ln #109
Website
First Ascent Arlington Heights
FITNESS
4.9 on Google · 551 reviews
701 Rohlwing Rd
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Amanda Arnold, LDN
RD
Registered dietitian
1051 W Rand Rd # L02
Call 847-618-7460NPI 1063378347
Peggy Balboa, RD
RD
Registered dietitian
4646 N Marine Dr
Call 773-564-7400NPI 1154875516
Christina Burkard, M.S., R.D., L.D.N
RD
Registered dietitian
200 W Golf Rd
Call 847-990-5770NPI 1699978049
Theresa Desai, CDE
RD
Registered dietitian
1051 W Rand Rd # 110
Call 847-618-9292NPI 1780806687
Lisa Ennessy, RD, LDN
RD
Registered dietitian
2010 S Arlington Heights Rd
Call 847-228-3200NPI 1093881088
Marissa Fleming, MS, RDN, LDN
RD
Registered dietitian
2003 W Fulton St
Call 312-850-3438NPI 1649946393
§ 06Clinical evidence
N = 8,416 across SUSTAIN 1 to 7

What the trials actually showed.

We summarize results from the SUSTAIN program, the seven Phase III randomized trials Novo Nordisk submitted to the FDA, and the SUSTAIN-6 cardiovascular outcomes trial. Numbers below are means at the 30-week endpoint, 1 mg weekly dose.

SUSTAIN 1 through 7 compared semaglutide against placebo, sitagliptin, exenatide ER, insulin glargine, and dulaglutide. Semaglutide produced superior HbA1c and body-weight reductions in every active comparator trial.[3]
SUSTAIN endpoint table1 mg / 30 wk
HbA1c reduction
−1.4 to −1.8%
vs. placebo at 30 wk[3]
Weight change
−4.5 to −6.4 kg
mean, 1 mg dose[3]
Major adverse cardiac events
−26%
HR 0.74 vs. placebo[2]
Patients reaching HbA1c <7%
72%
1 mg dose, 30 wk[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Ozempic weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in SUSTAIN trials were nausea (15 to 20%), diarrhea (8 to 9%), and vomiting (5 to 9%), all dose-dependent and typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
15 to 20%
mild
Most common; typically dose-dependent and resolves within weeks
Diarrhea
8 to 9%
mild
More frequent during dose escalation
Vomiting
5 to 9%
mild
Reduced by slower titration
Constipation
3 to 7%
mild
Abdominal pain
5 to 7%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; black-box adjacent
Gallbladder disease
1.5%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$950 to $1,150
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $250
per month copay
Varies by PBM; T2D indication usually covered
Commercial insurance (off-label / weight)
Typically denied
PA required; majority denied for weight indication
Medicare Part D
$0 to $100
per month
T2D covered; weight loss not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Ozempic providers in Illinois

NPI-verified Ozempic (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Ozempic in other states

Find NPI-verified Ozempic (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Ozempic in Illinois

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is a federally scheduled prescription drug in all 50 states. A licensed prescriber (MD, DO, NP, or PA) must evaluate you before issuing a prescription. No state permits pharmacist-initiated prescribing of GLP-1s.[1]